Rep. Sherrill Calls for $10 Billion Investment in Biomedical Research

Biomedical Innovation Expansion Act invests in NIH to extend and provide new research funding for antibiotic resistance and rare diseases

Washington, DC — Representative Mikie Sherrill (NJ-11) introduced the Biomedical Innovation Expansion Act of 2019 this afternoon with Representatives Mike Levin (CA-49) and Abigail Spanberger (VA-07) to invest $10 billion over the next ten years in the National Institutes of Health (NIH) to provide support for scientific research related to antibiotic resistance and rare diseases.

The Biomedical Innovation Expansion Act of 2019 also provides steady, predictable resources through the NIH Innovation Fund, which was created through the bipartisan 21st Century Cures Act in 2016, and increases support for all current NIH Innovation Fund activities to 2030.

“For generations, New Jersey has been a world leader in biomedical research innovation,” said Representative Sherrill. “I’ve seen the exciting and breakthrough research happening right here in North Jersey that will help us save lives, improve health, and offer hope to people affected by rare diseases. This bill continues the momentum of support for biomedical research funding to ensure America remains a leader in research innovation and that we support jobs in New Jersey.”

“The National Institutes of Health support critically important research that improves the quality of life for people across the country, and we must make robust investments in that work,” said Representative Levin. “The Southern California communities I represent are home to world renowned research institutions, and the Biomedical Innovation Act will help ensure that they have the funding they desperately need.”

“Our country’s medical researchers have been recognized around the world for their cutting-edge discoveries, and this proud legacy of innovation has solidified our reputation as a global leader in the fight against rare diseases and chronic illnesses,” said Representative Spanberger. “The dedicated staff at the NIH deserve strong support for their world-class research, and this bill reaffirms the idea that the medical challenges of tomorrow can be addressed through the lifesaving research of today. This funding would help the next generation of scientists understand new ways to prevent antibiotic resistance, treat rare diseases, and eventually develop a cure for cancer. I’m proud to help introduce this legislation alongside Congresswoman Sherrill and Congressman Levin—and I’ll keep looking to support ways to develop new treatments, encourage innovation, and allow Central Virginia patients to live longer and healthier lives.”

The bill invests $10 billion over ten years in the National Institutes of Health as a catalyst for medical cures and scientific breakthroughs. This includes:

• Roughly $3 billion for the Precision Medicine Initiative, which includes the ambitious All of Us Research Program aimed at building a diverse database to inform thousands of studies on a variety of health conditions as an important way to accelerate health research;

• Over $2.9 billion for the Brain Research Advancing Innovative Neurotechnologies (BRAIN) Initiative and its goals set out in BRAIN 2025: A Scientific Vision, including the broad goal of gaining insight into how the nervous system functions in health and disease;

• More than $1.6 billion towards combating antimicrobial and antibiotic resistance, which the World Health Organization warns is one of the top ten threats to global health;

• $1.5 billion for the Beau Biden Cancer Moonshot to continue to accelerate cancer research for more patients in need;

• $758 million to support research on the several thousands of rare diseases without a treatment; and

• $220 million toward the Regenerative Medicine Innovation Project carried out in coordination with the Food and Drug Administration to advance the development of safe and effective regenerative medicine innovations using adult stem cells.

###